Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Intravesicular nanoparticulate drug delivery systems for application in bladder cancer

Funder: Canadian Institutes of Health Research

Funding period
CAD 292 K
USD 285 K
Funding amount
Abstract
Bladder cancer is the fifth most common cancer in Canada and the incidence is increasing. Superficial disease is treated by surgical removal of tumors and the intravesical instillation of chemotherapy agents, usually mitomycin C, directly into the bladder via a catheter. However, the highly impermeable barrier presented by the superficial umbrella cells of the bladder wall seriously limit drug uptake and effectiveness of intravesical chemotherapy and patients require life-long surveillance, usually with repeated interventions. New therapeutic approaches are urgently needed. We have developed tiny, spherical nano-sized particles that are very highly branched and possess a core that can carry a payload of docetaxel and a surface that can be modified with positively charged amine groups. These nanoparticles show markedly superior bladder tissue drug levels and efficacy in a mouse model of superficial bladder cancer and we believe this may be explained by the amine coated nanoparticles causing shedding of the surface barrier cells. We also found that, following removal of the nanoparticles and washing of the bladder tissue, the superficial cell layer was regenerated extremely rapidly, within hours. The goal of this translational research is to develop these unique drug nanoparticles for potential treatment of patients receiving intravesical chemotherapy after surgical resection of tumors. The objectives are to investigate the processes leading to superficial cell shedding and recovery, to determine the uptake and distribution of the drug and nanoparticles in bladder and tumor tissue and to evaluate the efficacy and toxicity of the drug loaded nanoparticles in mouse models of superficial bladder cancer.
Similar projects All >
Sorted by: Start Date
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Jonathan David Spicer, Ciriaco A. Piccirillo

USD 138,878
2020 - 2025
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Bioengineering

  • RCDC

    Nanotechnology

  • RCDC

    Cancer

  • RCDC

    Orphan Drug

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science